Multiple primary head and neck squamous cell cancer: Lessons learnt

被引:0
|
作者
Ghogale, Kshitish S. [1 ,2 ]
Naorem, Raphel [1 ,2 ]
Waghmare, Chaitali M. [1 ,2 ]
机构
[1] PIMS DU, Dr Vitthalrao Vikhe Patil Pravara Rural Hosp, Dept Radiat Oncol, Ahmednagar, Maharashtra, India
[2] PIMS DU, Dr Vitthalrao Vikhe Patil Pravara Rural Hosp, Dr Balasaheb Vikhe Patil Rural Med Coll, Ahmednagar, Maharashtra, India
关键词
Field cancerization; head and neck; multiple primary cancer; re-irradiation; squamous cell cancer; 2ND PRIMARY TUMORS; FIELD CANCERIZATION; SINGLE-INSTITUTION; CHANGING PATTERNS; PREVENTION; FAILURE; IMPACT; TRIAL; STAGE;
D O I
10.4103/jcrt.jcrt_392_22
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To analyze the demographic profile, treatment outcome, and factors affecting them in multiple primary head and neck squamous cell cancer (MPHNSCC) patients. Materials and Methods: Hospital case records of patients with histopathology proven MPHNSCC registered in the radiation oncology department from January 2008 to December 2020 were retrospectively studied. Modified Warren-Gates criteria were used to define MPHNSCC. Demographic and clinical details were recorded and analyzed. Results: Twenty-seven patients had histopathology proven MPHNSCC. The median age at diagnosis of an index case was 50 years (minimum 26, maximum 70) with a male to female sex ratio of 22:5. Seventeen (62.96%) patients were tobacco users; either smoked or smokeless. The oral cavity was the commonest sub-site for both an index and second primary malignancy (22 patients; 81.48%) and the majority presented in a locally advanced stage of disease (10; 37.03% and 16; 62.95% for an index and second primary, respectively). The presentation was simultaneous, synchronous, and metachronous in 1 (3.7%), 2 (7.4%), and 24 (88.89%) patients, respectively. Two patients had three sites of MPHNSCC. The average duration of chronicity was 54.37 months (min. 8 and max. 156). MPHNSCC were ipsilateral in 10 (37.04%) patients and re-irradiation was planned for 22 (81.48%) patients with 50% treatment compliance. At the time of the last hospital visit, 18 (66.66%) patients were alive with disease, 7 (25.92%) patients were alive without disease, and 2 (7.40%) patients died of disease. Conclusion: A higher percentage of MPHNSCC originated from the oral cavity and the majority presented in the locally advanced stage of disease; despite the site being accessible to self-oral examination. Patient education and physician's awareness regarding the MPHNSCC are needed.
引用
收藏
页码:S658 / S663
页数:6
相关论文
共 50 条
  • [1] Multiple primary head and neck squamous cell cancer: Lessons learnt
    Ghogale, Kshitish S.
    Naorem, Raphel
    Waghmare, Chaitali M.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 2) : S658 - S663
  • [2] MULTIPLE PRIMARY CANCERS IN SQUAMOUS-CELL CANCER OF THE HEAD AND NECK
    KOTWALL, C
    RAZACK, MS
    SAKO, K
    RAO, U
    JOURNAL OF SURGICAL ONCOLOGY, 1989, 40 (02) : 97 - 99
  • [3] MULTIPLE PRIMARY SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    HONG, WK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (02): : 182 - 183
  • [4] Head and neck squamous cell cancer
    Tryggvason, Geir
    Sveinsson, Porarinn E.
    Hjartarson, Hannes
    Halfdanarson, Porvarour R.
    LAEKNABLADID, 2009, 95 (10): : 671 - 680
  • [5] MULTIPLE PRIMARY CANCERS IN HONG-KONG CHINESE PATIENTS WITH SQUAMOUS-CELL CANCER OF THE HEAD OR NECK
    CHOY, ATK
    VANHASSELT, CA
    CHISHOLM, EM
    WILLIAMS, SR
    KING, WWK
    LI, AKC
    CANCER, 1992, 70 (04) : 815 - 820
  • [6] Docetaxel in squamous cell cancer of the head and neck
    Posner, MR
    ANTI-CANCER DRUGS, 2001, 12 : S21 - S24
  • [7] Progression of head and neck squamous cell cancer
    Tímár, J
    Csuka, O
    Remenár, É
    Répássy, G
    Kásler, M
    CANCER AND METASTASIS REVIEWS, 2005, 24 (01) : 107 - 127
  • [8] Progression of head and neck squamous cell cancer
    József Tímár
    Orsolya Csuka
    Éva Remenár
    Gábor Répássy
    Miklós Kásler
    Cancer and Metastasis Reviews, 2005, 24 : 107 - 127
  • [9] Squamous cell head and neck cancer in nonsmokers
    Tan, EH
    Adelstein, DJ
    Droughton, MLT
    VanKirk, MA
    Lavertu, P
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (02): : 146 - 150
  • [10] Immunotherapy in Head and Neck Squamous Cell Cancer
    Denaro, Nerina
    Merlano, Marco Carlo
    CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY, 2018, 11 (04) : 217 - 223